Strides Pharma shares rallied over 6% after the company reported robust earnings for Q4 FY25. As of 3 PM, the shares were trading 6.10% higher at Rs 737.95.
The pharmaceutical firm posted a consolidated operational net profit of ₹113 crore for the quarter, marking a nearly fivefold increase from ₹24 crore in Q4 FY24. Revenue grew 17% year-on-year (YoY) to ₹1,190.4 crore, up from ₹1,017.8 crore, supported by strong demand and improved product mix.
Operational efficiency also improved, with gross margins rising to ₹691.4 crore. The gross margin expanded to 58.1% from 57.5% in the same quarter last year. EBITDA stood at ₹217.9 crore, reflecting a 22% YoY growth, while EBITDA margin improved by 75 basis points to 18.3%.
For the full financial year FY25, the company reported revenue of ₹4,565.3 crore, a 17.2% increase YoY. EBITDA for the year surged 36.8% to ₹802.8 crore. Most notably, operational PAT jumped to ₹344.7 crore from ₹27.9 crore in FY24, highlighting a sharp turnaround in profitability.
Earnings per share (EPS) also showed significant growth, rising to ₹37.5 from ₹3.1 the previous year.
Strides Pharma shares opened at ₹690.10 today, reaching a high of ₹750.00 and a low of ₹680.00. The stock remains close to its 52-week high of ₹804.00, indicating strong recent performance. In contrast, the 52-week low stands at ₹329.86.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
